GlaxoSmithKline warns on profits as China bribes crisis bites
Thirty staff have been sacked in China amid allegations that doctors were bribed to use GSK’s products
Thursday 24 July 2014
GlaxoSmithKline slashed its growth forecasts and stopped a billion-pound plus share buyback yesterday as its chief executive, Sir Andrew Witty, said he remained “concerned” about allegations that it bribed doctors in China to prescribe its drugs.
A strong pound and falling sales of its key lung drugs in the US also hit the pharmaceutical giant’s results.
GSK shares dived on the news, falling as much as 6.9 per cent before ending down 73.5p, or nearly 5 per cent, at 1,481.5p – their lowest point since the China scandal broke just over a year ago.
Chinese officials have charged a private investigator, Peter Humphrey, who worked for GSK, and his wife, with illegally trading personal information, while sex tapes have come to light of its former China head Mark Reilly and his Chinese girlfriend.
Under-pressure Sir Andrew yesterday revealed another set of quarterly results with little sign of the promised recovery in sales’ growth. Revenues for the latest three months dropped 16 per cent to £5.56bn while core operating profits were down 25 per cent at £1.4bn.
Sales of GSK’s drugs and vaccines in the US fell by 10 per cent, mostly due to increased competition from generic drugs. Sales of its blockbuster asthma treatment Advair fell 12 per cent in the second quarter, having fallen by 15 per cent in the first.
The ongoing investigations in China also hit sales badly there, with revenues down by 20 per cent. Sir Andrew said that GSK took the allegations seriously and investigated every claim of wrongdoing, taking action if they had substance. “We have zero tolerance for unethical behaviour,” he said. “The vast majority of our employees operate ethically and we are continuing to cooperate with the Chinese investigations.”
Thirty staff have been sacked in China amid allegations that doctors were bribed to use GSK’s products.
Sir Andrew said GSK remained “committed to China” and expected sales growth there to “begin to recover” in the current third quarter. He also highlighted global new product launches but admitted that they were costing more to get to market and to sell.
GSK said it now expects no growth in earnings per share in 2014 against its previous indications of 4 to 8 per cent growth. It added that it would not now give any guidance on earnings prospects beyond the current year.
Mark Clark, an analyst at Deutsche Bank, said the City would have to cut earnings forecasts for the group by more than 5 per cent, and GSK’s poor performance could put its dividend policy under pressure.
Sir Andrew added: “Our good progress on newly launched products is being offset by pricing and contracting pressure in the US.
“As we highlighted last quarter, this has resulted in a ‘step change’ reduction in Advair market share and pricing, and it is now clear that these pressures are likely to continue.”
- 1 I was raped by another man. And now the Government wants to take away the one thing that saved my life
- 2 Preston fan who appeared to snatch Jermaine Beckford's shirt from eight-year-old boy identified and says: 'the truth will come out'
- 3 Priest warns pupils the 'Charlie Charlie Challenge' is 'demonic activity'
- 4 Iran launches anti-Isis cartoon competition 'to expose true nature of Islamic State'
- 5 US warned by Chinese media to stop meddling or 'war will be inevitable'
Australian man punched in the face for defending Muslim women from abuse on train
Priest warns pupils the 'Charlie Charlie Challenge' is 'demonic activity'
Iran launches anti-Isis cartoon competition 'to expose true nature of Islamic State'
Woman accidentally shoots herself in the head while posing for a selfie
US warned by Chinese media to stop meddling or 'war will be inevitable'
As a white man, I'm surprised more women aren't tweeting the hashtag #KillAllWhiteMen
EU referendum: David Cameron's rules are a 'democratic disgrace', says French-born Scottish politician set to be denied a vote
The day that Britain resigned as a global power
SNP fury as HS2 finds 'no business case' for taking fast train service to Scotland
A nation of inequality: How the UK is failing to feed its most vulnerable people
EU referendum: David Cameron to deny EU migrants and under-18s the chance to vote
iJobs Money & Business
£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is a mul...
£55 - 65k (DOE): Guru Careers: A unique opportunity for a permanent C# Develop...
£16 - 20k: Guru Careers: A Graduate Editor / Editorial Assistant is needed to ...
£40-50K: Guru Careers: We are seeking an experienced Software / C# Developer w...